Advances in the non-surgical treatment of melanoma

被引:14
作者
Hersey, P [1 ]
机构
[1] Immunol & Oncol Unit, Newcastle, NSW 2300, Australia
关键词
clinical trial; melanoma; vaccine;
D O I
10.1517/13543784.11.1.75
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Immune responses appear to play a role in the natural history of melanoma and immunotherapy has therefore been the subject of a number of studies. The results of several large randomised studies using allogeneic melanoma vaccines have shown minimal benefit and Phase I/II studies with gene transfected melanoma cells do not appear particularly encouraging. The majority of current interest now centres on development of vaccines using defined melanoma antigens recognised by T-cells and given as dendritic vaccines or injected directly as melanoma peptides or DNA. It can be expected that the most effective antigens and method of administration will become apparent over the next few years. It is clear, however, that melanoma shows low response rates to immunotherapy, as for chemotherapy. Both forms of therapy appear to kill melanoma by induction of apoptosis, so it is possible that resistance to apoptosis may underlie the low responses to these forms of therapy. Much is already known about agents that may sensitise melanoma to apoptosis and combining these with chemotherapy and/or immunotherapy provides a promising new approach in treatment of melanoma.
引用
收藏
页码:75 / 85
页数:11
相关论文
共 80 条
  • [1] Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
    Arienti, F
    Belli, F
    Napolitano, F
    Sulé-Suso, J
    Mazzocchi, A
    Gallino, GF
    Cattelan, A
    Sanantonio, C
    Rivoltini, L
    Melani, C
    Colombo, MP
    Cascinelli, N
    Maio, M
    Parmiani, G
    [J]. HUMAN GENE THERAPY, 1999, 10 (18) : 2907 - 2916
  • [2] Apoptosis control by death and decoy receptors
    Ashkenazi, A
    Dixit, VM
    [J]. CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (02) : 255 - 260
  • [3] Atkins Michael B., 1997, Current Opinion in Oncology, V9, P205
  • [4] Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability
    Belli, F
    Arienti, F
    SuleSuso, J
    Clemente, C
    Mascheroni, L
    Cattelan, A
    Sanantonio, C
    Gallino, GF
    Melani, C
    Rao, S
    Colombo, MP
    Maio, M
    Cascinelli, N
    Parmiani, G
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 44 (04) : 197 - 203
  • [5] Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases
    Berd, D
    Maguire, HC
    Schuchter, LM
    Hamilton, R
    Hauck, WW
    Sato, T
    Mastrangelo, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2359 - 2370
  • [6] Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO
  • [7] 2-0
  • [8] Bystryn JC, 2001, CLIN CANCER RES, V7, P1882
  • [9] CEBON JS, 1999, P ASCO, V18, pA434
  • [10] Chakraborty N., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P400